Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Dare Bioscience, Inc. (NASDAQ: DARE).

Full DD Report for DARE

You must become a subscriber to view this report.


Recent News from (NASDAQ: DARE)

EY Announces that Sabrina Martucci Johnson, CEO of Daré Bioscience, Inc., is an Entrepreneur Of The Year® 2018 Award Finalist in San Diego
SAN DIEGO, May 16, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced today that President and CEO Sabrina Martucci Johnson is a finalis...
Source: GlobeNewswire
Date: May, 16 2018 08:00
Daré Bioscience, Inc. Announces Trial Initiation for Ovaprene® Non-Hormonal Monthly Contraceptive Candidate
SAN DIEGO, May 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced today the initiation of its post-coital test (PCT) clinical trial ...
Source: GlobeNewswire
Date: May, 15 2018 08:00
Daré Bioscience, Inc. Expands Leadership Team, Appointing John Fair to Chief Business Officer
SAN DIEGO, May 08, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced it has appointed Mr. Fair to the newly created position of Chief Business Officer. Mr. Fair’s role will include business a...
Source: GlobeNewswire
Date: May, 08 2018 08:00
Premarket Gainers as of 9:05 am (05/07/2018)
DARE +29%  on  entering into a merger agreement with Pear Tree Pharmaceuticals. More news on: Dare Bioscience, Inc., Gramercy Property Trust, Inc., Auris Medical Holding, , Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 07 2018 09:14
Daré Bioscience, Inc. Enters into Agreement to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone Receptor-Positive Breast Cancer Patients
Agreement intends to broaden Company’s product portfolio within women’s reproductive health with novel clinical candidate, positioning Company with first in class candidates in contraception, sexual health and vaginal health SAN DIEGO, May 07, 2018 (GLOBE NEWSWIRE) -- Da...
Source: GlobeNewswire
Date: May, 07 2018 08:00
Daré Bioscience announces funding award to further the development of Ovaprene(TM) from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
SAN DIEGO, April 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it received a Notice of Award for the first $224,665 of the anticipated $1.9 million in grant funding from the...
Source: GlobeNewswire
Date: April, 30 2018 08:00
Today's Research Reports on Stocks to Watch: Dare Bioscience and ACADIA
NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Dare Biosicence shares were exploding on Wednesday after the women's biopharma company announced that it had entered into an exclusive worldwide license agreement for Juniper Pharmaceutical's Intravaginal Ring technology platform. Shares of Arcad...
Source: ACCESSWIRE IA
Date: April, 26 2018 08:10
Daré Bioscience in-licenses contraceptive ring from Juniper Pharma; shares up 52%
Daré Bioscience ( DARE +51.8% ) has secured exclusive rights to Juniper Pharmaceuticals' ( JNP ) contraceptive intravaginal ring technology. Its value proposition is sustained drug delivery without the need for a membrane or reservoir to contain the active ingredient or control its ...
Source: SeekingAlpha
Date: April, 25 2018 11:19
Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals' Intravaginal Ring (IVR) Technology Platform
SAN DIEGO, April 25, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced today it has secured an exclusive license to Juniper Pharmaceuti...
Source: GlobeNewswire
Date: April, 25 2018 08:00
Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US
Stock Monitor: Dare Bioscience Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on BiondVax Pharma Ltd (NASDAQ: BVXV ) (''BiondVax''). If you want access to this report all you need to do is sign up now by...
Source: ACCESSWIRE IA
Date: April, 13 2018 07:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-171.111.1611.221.07762,617

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17124,959448,70327.8489Cover
2018-08-1614,63038,30638.1925Short
2018-08-1511,27938,36929.3961Cover
2018-08-1431,98341,26577.5064Short
2018-08-1330,68483,50136.7469Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DARE.


About Dare Bioscience, Inc. (NASDAQ: DARE)

Logo for Dare Bioscience, Inc. (NASDAQ: DARE)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $3,106,395 - 05/15/2018
    • Issue and Outstanding: 2,903,173 - 07/20/2017

     


    Recent Filings from (NASDAQ: DARE)

    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 14 2018
    Filing Type: CT ORDERFiling Source: edgar
    Filing Date: May, 08 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 04 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 30 2018
    Amendment to a previously filed 10-K
    Filing Type: 10-K/AFiling Source: edgar
    Filing Date: April, 30 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 11 2018
    Annual report with a comprehensive overview of the company
    Filing Type: 10-KFiling Source: edgar
    Filing Date: March, 28 2018
    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: February, 22 2018
    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: February, 21 2018
    Amendment to the SC 13G filing
    Filing Type: SC 13G/AFiling Source: edgar
    Filing Date: February, 14 2018

     

     


    Daily Technical Chart for (NASDAQ: DARE)

    Daily Technical Chart for (NASDAQ: DARE)


    Stay tuned for daily updates and more on (NASDAQ: DARE)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: DARE)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DARE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of DARE and does not buy, sell, or trade any shares of DARE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/